See more : Valor Latitude Acquisition Corp. (VLATW) Income Statement Analysis – Financial Results
Complete financial analysis of Amyris, Inc. (AMRS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Amyris, Inc., a leading company in the Chemicals – Specialty industry within the Basic Materials sector.
You may be interested
- JCDecaux SE (JCDXF) Income Statement Analysis – Financial Results
- Nepra Foods Inc. (NPRA.CN) Income Statement Analysis – Financial Results
- Aegon N.V. (AEGOF) Income Statement Analysis – Financial Results
- Global Resource Energy, Inc. (GBEN) Income Statement Analysis – Financial Results
- Oragenics, Inc. (OGEN) Income Statement Analysis – Financial Results
Amyris, Inc. (AMRS)
About Amyris, Inc.
Amyris, Inc., a synthetic biotechnology company, operates in the clean health and beauty, and flavors and fragrance markets in Europe, North America, Asia, and South America. The company manufactures and sells clean beauty, personal care, and health and wellness consumer products, as well as ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets. It offers its products under the Biossance, Pipette, Purecane, Terasana, Costa Brazil, OLIKA, Rose Inc., and JVN brand names. The company has a collaboration agreement with the Infectious Disease Research Institute for the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was incorporated in 2003 and is headquartered in Emeryville, California.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 269.85M | 341.82M | 173.14M | 152.56M | 80.42M | 143.45M | 77.19M | 34.15M | 43.27M | 41.12M | 73.69M | 146.99M | 80.31M | 64.61M | 13.89M |
| Cost of Revenue | 258.67M | 155.14M | 87.81M | 76.19M | 38.91M | 63.83M | 56.68M | 37.37M | 33.20M | 38.25M | 77.31M | 155.62M | 70.52M | 60.43M | 10.36M |
| Gross Profit | 11.18M | 186.68M | 85.33M | 76.37M | 41.51M | 79.62M | 20.51M | -3.22M | 10.07M | 2.87M | -3.62M | -8.62M | 9.80M | 4.18M | 3.53M |
| Gross Profit Ratio | 4.14% | 54.61% | 49.28% | 50.06% | 51.62% | 55.50% | 26.58% | -9.43% | 23.27% | 6.97% | -4.91% | -5.87% | 12.20% | 6.47% | 25.40% |
| Research & Development | 110.22M | 94.29M | 71.68M | 71.46M | 68.69M | 56.84M | 51.41M | 44.64M | 49.66M | 56.07M | 73.63M | 87.32M | 55.25M | 38.26M | 30.31M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 493.63M | 257.81M | 137.07M | 126.59M | 86.92M | 63.03M | 47.72M | 56.26M | 55.44M | 57.05M | 78.72M | 83.23M | 40.39M | 23.56M | 16.62M |
| Other Expenses | 0.00 | -38.07M | -89.16M | -20.15M | 1.36M | -956.00K | -45.37M | -114.18M | -30.00M | -20.86M | -45.63M | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 603.84M | 352.10M | 208.75M | 198.05M | 155.61M | 119.88M | 99.13M | 105.62M | 105.10M | 113.12M | 152.35M | 170.55M | 95.64M | 61.82M | 46.93M |
| Cost & Expenses | 862.51M | 507.24M | 296.56M | 274.23M | 194.52M | 183.71M | 155.81M | 143.00M | 138.30M | 151.37M | 229.66M | 326.16M | 166.16M | 122.25M | 57.29M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 258.00K | 264.00K | 387.00K | 162.00K | 1.47M | 1.54M | 1.54M | 448.00K | 1.38M |
| Interest Expense | 24.73M | 25.61M | 47.95M | 58.67M | 39.27M | 36.16M | 37.63M | 78.85M | 28.95M | 9.11M | 4.93M | 1.54M | 1.44M | 1.22M | 377.00K |
| Depreciation & Amortization | 27.27M | -25.38M | -77.04M | -20.15M | 4.92M | 11.36M | 11.37M | 12.92M | 14.97M | 16.64M | 14.57M | 11.08M | 7.28M | 5.78M | 2.63M |
| EBITDA | -514.21M | -190.80M | -200.46M | -141.83M | -112.74M | -41.22M | -115.83M | -118.46M | -225.62M | -5.61M | -200.13M | -166.55M | -81.53M | -51.42M | -39.40M |
| EBITDA Ratio | -190.55% | -55.82% | -115.78% | -92.97% | -140.19% | -28.73% | -150.05% | -346.86% | -521.36% | -13.64% | -271.56% | -113.31% | -101.51% | -79.58% | -283.58% |
| Operating Income | -592.67M | -165.42M | -123.42M | -121.67M | -120.95M | -40.26M | -85.92M | -148.53M | -99.83M | -119.62M | -201.82M | -179.17M | -83.79M | -63.41M | -43.40M |
| Operating Income Ratio | -219.63% | -48.39% | -71.29% | -79.76% | -150.40% | -28.07% | -111.31% | -434.90% | -230.69% | -290.90% | -273.86% | -121.89% | -104.33% | -98.14% | -312.41% |
| Total Other Income/Expenses | 54.04M | -106.89M | -200.43M | -120.46M | -28.16M | -36.84M | -10.86M | -69.05M | 102.49M | -116.14M | -3.23M | 213.00K | 2.96M | -1.39M | 857.00K |
| Income Before Tax | -538.63M | -272.31M | -323.85M | -242.14M | -211.35M | -77.10M | -86.78M | -217.58M | 2.66M | -235.75M | -205.05M | -178.96M | -80.83M | -64.80M | -42.54M |
| Income Before Tax Ratio | -199.60% | -79.67% | -187.05% | -158.72% | -262.81% | -53.75% | -112.42% | -637.09% | 6.15% | -573.35% | -278.25% | -121.75% | -100.64% | -100.30% | -306.24% |
| Income Tax Expense | -2.70M | -8.11M | 293.00K | 629.00K | -50.95M | 295.00K | 553.00K | 468.00K | 495.00K | -847.00K | 981.00K | 552.00K | -3.98M | 877.00K | -207.00K |
| Net Income | -535.93M | -264.20M | -324.14M | -242.77M | -211.35M | -77.39M | -87.33M | -217.95M | 2.29M | -235.11M | -205.14M | -178.87M | -81.87M | -64.46M | -41.86M |
| Net Income Ratio | -198.60% | -77.29% | -187.22% | -159.13% | -262.81% | -53.95% | -113.14% | -638.16% | 5.28% | -571.78% | -278.37% | -121.69% | -101.94% | -99.77% | -301.35% |
| EPS | -1.58 | -0.90 | -1.59 | -2.39 | -3.50 | -2.40 | -5.49 | -25.75 | 0.45 | -46.73 | -54.25 | -59.89 | -82.75 | -203.42 | -124.74 |
| EPS Diluted | -1.58 | -0.90 | -1.59 | -2.39 | -3.50 | -2.40 | -4.95 | -25.75 | 0.28 | -46.73 | -54.25 | -59.89 | -82.75 | -203.42 | -124.74 |
| Weighted Avg Shares Out | 339.33M | 292.34M | 203.60M | 101.37M | 60.36M | 32.25M | 15.90M | 8.46M | 5.23M | 5.03M | 3.78M | 2.99M | 989.36K | 316.87K | 335.61K |
| Weighted Avg Shares Out (Dil) | 339.33M | 292.67M | 203.60M | 101.37M | 60.36M | 32.25M | 17.64M | 8.46M | 8.12M | 5.03M | 3.78M | 2.99M | 989.36K | 316.87K | 335.61K |
Are Options Traders Betting on a Big Move in Amyris (AMRS) Stock?
Investors need to pay close attention to Amyris (AMRS) stock based on the movements in the options market lately.
The 7 Best Green Energy Stocks to Grow Your Portfolio in 2022
Green Energy stocks look to be coming back into vogue in 2022 making these seven plays attractive for the longer term. The post The 7 Best Green Energy Stocks to Grow Your Portfolio in 2022 appeared first on InvestorPlace.
BIGZ: Innovation Goes Into Meltdown
BIGZ: Innovation Goes Into Meltdown
3 Beaten-Down Growth Stocks to Buy for 2022
After falling by at least a third over the past month, these former highfliers are poised to reach new heights in the new year.
Amyris: Well Positioned In The Cannabinoids Market
Amyris is the only synthetic biology company developing and manufacturing a portfolio of products at scale. Biosynthesis of cannabinoids reduces regulatory concerns and makes minor cannabinoids commercially viable.
3 Growth Stocks to Fuel Your 2022 Financial Freedom
This basket of industrial and electric vehicle stocks is primed to pole vault your portfolio.
Amyris: Vaccine Upside
Amyris is the only synthetic biology company developing and manufacturing a portfolio of products at scale. Amyris has obtained access to differentiated vaccine technology through a licensing arrangement with the Infectious Disease Research Institute.
Amyris Buying Opportunity Created By Q3 Miss, Mega Convert And Potential Revolutionary COVID Vaccine
Big Revenue miss for Q3 due to supply chain shortages and Amyris guides lower for Q4. Surprise $690 million convert is less dilutive (12%, not 18%) and at a beneficially higher effective conversion price ($15.90, not $10.75/share) due to a...
Amyris: Valuations Are Attractive After Hype Around Synthetic Biotech Is Quelled By CEO's Ambitious Guidance
Amyris' synthetic biotechnology breakthrough with squalene. The real crown jewel of Amyris' current business segment.
Why Shares of Amyris Are Plummeting This Week
There's nothing artificial about the plunging price of this synthetic biology stock.
Source: https://incomestatements.info
Category: Stock Reports